JP2023543896A - 抗アデノシン受容体（Ａ２ａＲ）抗体 - Google Patents

抗アデノシン受容体（Ａ２ａＲ）抗体 Download PDF

Info

Publication number
JP2023543896A
JP2023543896A JP2023520021A JP2023520021A JP2023543896A JP 2023543896 A JP2023543896 A JP 2023543896A JP 2023520021 A JP2023520021 A JP 2023520021A JP 2023520021 A JP2023520021 A JP 2023520021A JP 2023543896 A JP2023543896 A JP 2023543896A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
a2ar
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543896A5 (https=
Inventor
シュイン リウ，
シンヤン ジャオ，
チャンユン フー，
Original Assignee
エヌエー バイオテック コーポレイション
アデプト バイオファーマシューティカル アンド テクノロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌエー バイオテック コーポレイション, アデプト バイオファーマシューティカル アンド テクノロジー リミテッド filed Critical エヌエー バイオテック コーポレイション
Publication of JP2023543896A publication Critical patent/JP2023543896A/ja
Publication of JP2023543896A5 publication Critical patent/JP2023543896A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023520021A 2020-09-30 2021-09-30 抗アデノシン受容体（Ａ２ａＲ）抗体 Pending JP2023543896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085612P 2020-09-30 2020-09-30
US63/085,612 2020-09-30
PCT/US2021/052819 WO2022072601A1 (en) 2020-09-30 2021-09-30 ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2023543896A true JP2023543896A (ja) 2023-10-18
JP2023543896A5 JP2023543896A5 (https=) 2024-10-08

Family

ID=80951827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520021A Pending JP2023543896A (ja) 2020-09-30 2021-09-30 抗アデノシン受容体（Ａ２ａＲ）抗体

Country Status (7)

Country Link
US (1) US20230340132A1 (https=)
EP (1) EP4222173A4 (https=)
JP (1) JP2023543896A (https=)
CN (1) CN116348140A (https=)
AU (1) AU2021351500A1 (https=)
CA (1) CA3194285A1 (https=)
WO (1) WO2022072601A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CN116333127B (zh) * 2022-06-28 2026-03-24 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN119303103A (zh) * 2023-07-11 2025-01-14 清华大学 一种抗体偶联物及其应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025257365A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Adenosine a2a antagonists for the treatment of endometriosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011097869A (ja) * 2009-11-05 2011-05-19 Japan Science & Technology Agency 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体
US20140322236A1 (en) * 2013-03-15 2014-10-30 Sdix, Llc Anti-human adora2a antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2013040358A2 (en) * 2011-09-14 2013-03-21 University Of Washington Through Its Center For Commercialization Assays and compositions for detection of agr2
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
DK3515478T3 (da) * 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
WO2020185739A1 (en) * 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011097869A (ja) * 2009-11-05 2011-05-19 Japan Science & Technology Agency 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体
US20140322236A1 (en) * 2013-03-15 2014-10-30 Sdix, Llc Anti-human adora2a antibodies

Also Published As

Publication number Publication date
AU2021351500A2 (en) 2023-08-10
AU2021351500A1 (en) 2023-06-08
WO2022072601A1 (en) 2022-04-07
CN116348140A (zh) 2023-06-27
AU2021351500A9 (en) 2024-09-05
EP4222173A1 (en) 2023-08-09
CA3194285A1 (en) 2022-04-07
EP4222173A4 (en) 2024-10-30
US20230340132A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US12404336B2 (en) Bispecific antagonist comprising a LAG-3 binding domain
US20260014253A1 (en) Checkpoint regulator antagonists
JP2023543896A (ja) 抗アデノシン受容体（Ａ２ａＲ）抗体
US20200231665A1 (en) Antagonists targeting the tgf-b pathway
US20250206828A1 (en) ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES AND THE USE THEREOF
JP2025511270A5 (https=)
US20250171542A1 (en) Anti-programmed death-ligand 1 (pd-l1) antibodies
HK40124840A (zh) 抗腺苷受体(a2ra)抗体及其用途
WO2023192289A2 (en) Anti-trophoblast cell surface antigen 2 (trop-2) antibodies
EA045974B1 (ru) Противоопухолевые антагонисты регуляторов иммунных контрольных точек

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260410